US2005152960A1PendingUtilityA1
Use of green porphyrins to treat neovasculature in the eye
Priority: Mar 14, 1994Filed: Nov 5, 2004Published: Jul 14, 2005
Est. expiryMar 14, 2014(expired)· nominal 20-yr term from priority
A61K 9/0019A61K 9/1275A61K 49/0036A61K 49/0084A61K 41/0071A61F 9/008A61K 31/555A61K 31/409
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.
Claims
exact text as granted — not AI-modified1 - 20 . (canceled)
21 . A method of treating unwanted choroidal neovasculature in a shortened treatment time, the method comprising the steps of:
administering to a primate subject in need of such treatment an amount of a porphyrin dye sufficient to permit an effective amount to localize in the neovasculature; and irradiating the neovasculature with light having an irradiance in the range from at least about 300 mW/cm 2 to about 900 mW/cm 2 , the light being absorbed by the porphyrin dye so as to occlude the neovasculature.
22 . The method of claim 21 , wherein the porphyrin is green porphyrin.
23 . The method of claim 25 , wherein the light has a fluence of 50 Joules/cm 2 .
24 . The method of claim 21 , wherein the primate subject has age-related macular degeneration and occlusion of the neovasculature ameliorates symptoms of the age-related macular degeneration.
25 . The method of claim 22 , wherein the primate subject has a disorder selected from the group consisting of age related macular degeneration, ocular histoplasmosis syndrome and myopia, wherein occlusion of the neovasculature ameliorates the disorder.
26 . A method of treating age-related macular degeneration in a primate subject having unwanted choroidal neovasculature in a shortened treatment time, the method comprising the steps of:
administering to the primate subject an amount of a green porphyrin dye sufficient to permit an effective amount to localize in the neovasculature; and irradiating the neovasculature with light having an irradiance in the range from at least about 300 mW/cm 2 to about 900 mW/cm 2 , the light being absorbed by the porphyrin dye so as to occlude the neovasculature.
27 . The method of claim 26 , wherein the light has a fluence of 50 Joules/cm 2 .Join the waitlist — get patent alerts
Track US2005152960A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.